To use all functions of this page, please activate cookies in your browser.
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
QIAGEN has Licensed a Novel Algorithm Developed by Novartis for the Selection of siRNA Sequences for Gene Silencing Applications
16-12-2003: QIAGEN N.V. announced that it has licensed from Novartis Pharma AG a novel algorithm for the selection of highly functional target sequences for RNA interference applications. More than 3000 randomly designed synthetic siRNA duplexes, against 34 targets were analyzed for functionality. Based on this large data set, an automated siRNA sequence selection algorithm was developed. Extensive evaluation of the new algorithm has demonstrated a significant performance improvement over existing design methods.
Under the terms of this collaboration QIAGEN obtained a fully paid-up license from Novartis for the worldwide use of this prediction algorithm. Financial terms were not disclosed.
"We are very happy that Novartis has made this new resource available to QIAGEN", said Patrick A. Weiss, QIAGEN's Vice President of Gene Silencing and co-inventor of the TOM RNA chemistry. "This powerful tool complements QIAGEN's state of the art synthesis technology, combining biological functionality with high quality siRNA. This means that researchers can focus on their experiments and not on developing functional gene targeting reagents."
This is where you can add this news to your personal favourites
- 1Rosetta Resolver® Gene Expression Data Analysis System licensed by Aventis Pharmaceuticals, Inc.
- 2Pharma’s New Hero: Supergenerics Save Money and Improve Drugs
- 3Pro Bono Bio Launches Flexiseq: A Novel Approach to the Treatment of Osteoarthritis
- 4Researchers divide enzyme to conquer genetic puzzle
- 5Merck & Co., Inc. Opens Asia Pacific Regional Headquarters in Singapore
- 6Pharmexa enters into an agreement regarding GV1001 with the Korean company KAEL Co. Ltd
- 7Pharmexa A/S sells Pharmexa-Epimmune to the Korean company VaxOnco, Inc.
- 8Sanofi-aventis to acquire Oenobiol
- 9MIV-210 - a potential drug against hepatitis B and HIV - enters phase II
- 10Vivacta Initiates Development of Point of Care Test for Vitamin D
- Resolutions of the Annual General Meeting of Evotec
- ZEISS to acquire Xradia to complement its microscopy business
- DHL launches industry-changing temperature controlled Life Sciences air frei ...
- Novasep appoints Udo Steinhauer as fine chemicals market director
- Merck’s credit rating raised by Standard & Poor’s to ‘A’